Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Vig

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Hepatology|May 27, 2018
Macrophages contribute to the pathogenesis of sclerosing cholangitis in miceMaria Eugenia Guicciardi, Christy E Trussoni, Anuradha Krishnan, et al.
Journal of Hepatology|August 29, 2021
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening populationMette Juul Nielsen, Diana Julie Leeming, Zachary Goodman, et al.
Hepatology Communications|May 15, 2023
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot studyChristopher L Bowlus, Bertus Eksteen, Angela C Cheung, et al.
Journal of Hepatology|September 23, 2017
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4Gamal Esmat, Tamer Elbaz, Maissa El Raziky, et al.
Hepatology Communications|May 4, 2022
Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 studyKathleen M Loomes, Robert H Squires, Deirdre Kelly, et al.
Lancet (London, England)|November 10, 2021
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 studyEmmanuel Gonzales, Winita Hardikar, Michael Stormon, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2025
Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 studyYaz Y Kisanuki, Paulo R Nobrega, Ryan Himes, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
The Lancet. Gastroenterology & Hepatology|May 9, 2024
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialAlexander G Miethke, Adib Moukarzel, Gilda Porta, et al.
Hepatology (Baltimore, Md.)|December 26, 2023
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALABettina E Hansen, Shannon M Vandriel, Pamela Vig, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Hepatology|May 27, 2018
Macrophages contribute to the pathogenesis of sclerosing cholangitis in miceMaria Eugenia Guicciardi, Christy E Trussoni, Anuradha Krishnan, et al.
Journal of Hepatology|August 29, 2021
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening populationMette Juul Nielsen, Diana Julie Leeming, Zachary Goodman, et al.
Hepatology Communications|May 15, 2023
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot studyChristopher L Bowlus, Bertus Eksteen, Angela C Cheung, et al.
Journal of Hepatology|September 23, 2017
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4Gamal Esmat, Tamer Elbaz, Maissa El Raziky, et al.
Hepatology Communications|May 4, 2022
Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 studyKathleen M Loomes, Robert H Squires, Deirdre Kelly, et al.
Lancet (London, England)|November 10, 2021
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 studyEmmanuel Gonzales, Winita Hardikar, Michael Stormon, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2025
Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 studyYaz Y Kisanuki, Paulo R Nobrega, Ryan Himes, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
The Lancet. Gastroenterology & Hepatology|May 9, 2024
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialAlexander G Miethke, Adib Moukarzel, Gilda Porta, et al.
Hepatology (Baltimore, Md.)|December 26, 2023
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALABettina E Hansen, Shannon M Vandriel, Pamela Vig, et al.
Pageof 3